Second primary malignancies in head and neck cancer patients

Wolff, Hendrik A.; Wolff, Cornelia; Hess, Clemens F.; Jung, Klaus; Sennhenn-Kirchner, Sabine; Hinterthaner, Marc; Müller-Dornieden, Annegret; Körber, W; Marten-Engelke, K.; Roedel, Ralph M.W.; Christiansen, Hans; Engelke, Christoph

doi:10.1007/s00066-013-0404-4

Cited by 9 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The incidence of a synchronous lung tumor in these cases is 1%, whereas the incidence of a metachronous tumor increases to 10% in patients who have survived ≥3 years (7,10). When the location of primary malignancies was analyzed in the present study, the second most frequent group was respiratory system malignancies with ten cases (22.2%); laryngeal cancer and lung cancer were included in this group.…”

Section: Discussionmentioning

confidence: 63%

Malignite tanılı opere edilmiş ikinci primer akciğer kanserli hastaların uzun dönem sağkalımını etkileyen faktörlerin analizi

Ergönül¹,

Özdil²,

Akçam³

et al. 2015

Ege Tıp Dergisi

View full text Add to dashboard Cite

Aim: Multiple cancer rates increase with an average increased lifespan. Therefore, many malignant patients are at high risk for a second primary malignancy. This study aims to evaluate lung cancer patients with a previous malignancy. Materials and Methods:Forty-five patients who underwent resection for a second primary lung cancer in our department between January 2007 and June 2013 were reviewed retrospectively. Results:The patients included 37 (82.2%) males and eight (17.8%) females. When the patients were evaluated for the first primary malignancy, the distribution of the malignancies according to the systems was 14 (31.1%) urogenital malignancies, ten (22.2%) respiratory, six (13.3%) hematological, six (13.3%) endocrine, five (11.1%) malignancies, and four (8.9%) integumentary malignancies. The comparison of the site of primary malignancy and survival data showed that the rates of long-term survival were shorter in patients with gastrointestinal system malignancies and the difference was statistically significant (p=0.028). The long-term survival of patients who received chemotherapy after the resection of the first primary lung cancer was significantly shorter (p=0.016). Conclusion:The follow-up of patients should be done more carefully by the consideration of the positive effects of early diagnosis on cancer prognosis and keeping in mind the risk of primary lung cancer development in a patient with other system malignancy. We especially recommend caution in administering chemotherapy to patients with double primary tumors after a lung cancer operation. Keywords

show abstract

Section: Discussionmentioning

confidence: 63%

Malignite tanılı opere edilmiş ikinci primer akciğer kanserli hastaların uzun dönem sağkalımını etkileyen faktörlerin analizi

Ergönül¹,

Özdil²,

Akçam³

et al. 2015

Ege Tıp Dergisi

View full text Add to dashboard Cite

show abstract

“…[16] Wolff et al showed that CT detected 13 of the 21 histolologically proven diagnosis of SPC with a falsepositive rate of 40.7%. 15 In contrast, Swensen et al…”

Section: Referencesmentioning

confidence: 95%

“…This study demonstrated that performing ENT-endo was recommended as part of systematic evaluation to detect SPC, with overall detection rate of 2.5%. 15 Petit et al reported that in 1560 patients with HNSCC the SPC incidence rate was 3.2% when endoscopy was applied twice annually over a period of 10 years. 16 CT is another method to detect SPC.…”

Section: Referencesmentioning

confidence: 99%

Second Primary Tumors in Patients with Head and Neck Cancer: A Retrospective Study from a Single Center

Gümüşsoy¹,

Özet²,

Baykara³

et al. 2014

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

262he development of a second malignant neoplasm was about 10-40% in patients with head and neck squamous cell carcinoma (HNSCC). Metachronous second cancers most frequently involve the esophagus and lung, whereas synchronous second cancers are more common in head Second Primary Tumors in Patients with Head and Neck Cancer: A Retrospective Study from a Single Center A AB BS S T TR RA AC CT T O Ob bj je ec ct ti iv ve e: : Patients with squamous cell carcinoma of the head and neck are at risk for developing a second primary cancer. The aim of this study was to determine incidence and localization of second primary tumors. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : Three hundred twenty-four patients with head and neck cancer diagnosed between 2000 -2010 were analyzed for the presence of a second malignancy. The data used in this study were obtained retrospectively from a database. R Re es su ul lt ts s: : A total of 324 patients were enrolled in this study, there were 248 males and 76 females ranging between the ages of 18 and 84 years, with a median age of 53 years. Ten patients (3.08%) had metachronous, three patients (0.93%) had synchronous cancers. In our study, 7.12% of the older population (>60 years) had second primary tumors, and 2.46% of the younger population (≤ 60 years) had second primary cancers. There were no statistical differences between two groups (p=0.07). Overall survival of patients with metachronous second primary cancers at 1 and 3 years were 87.5% and 62.5% respectively while these rates were 95.2% and 88.3% respectively in the ones without second primary cancers. C Co on nc cl lu us si io on n: : In our study, 4% of patients had second primary tumors. Screening programs were considered beneficial in high risk patients with head and neck cancers who smoke and use alcohol in order to detect second primary cancers.K Ke ey y W Wo or rd ds s: : Carcinoma, squamous cell of head and neck; neoplasms, second primary Ö ÖZ ZE ET T A Am ma aç ç: : Baş boyun skuamöz hücreli kanser hastaları, ikinci primer gelişimi açısından risklidir. Bu çalışmanın amacı, baş boyun kanserli hastalarda ikinci primer kanser insidansı ve lokalizasyonu araştırmaktır. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Çalışmaya 2000 ile 2010 yılları arasında, Gazi Üniversitesi Hastanesi'nde baş boyun kanseri tanısı alan 324 hasta dahil edildi. Çalışmada retrospektif veri tabanı oluşturularak analiz yapıldı. B Bu ul lg gu ul la ar r: : Hastaların 248'i erkek, 76'sı kadındı. Ortanca yaş 53 yıl (18-84 yıl) olarak saptandı. Hastaların 10'unda (%3,08) metakron, 3'ünde (%0,83) senkron ikinci primer vardı. Yaşlı hastaların (> 60 yaş) %7,12'sinde, 60 yaş ve daha genç hastaların %2,46'sında ikinci primer kanser geliştiği gözlendi. Bu iki grup arasında istatistiksel fark yoktu (p=0,07). Ortanca sağkalım ikinci primer gelişen grupta 1 yıllık %87,5, 3 yıllık %62,5 iken, gelişmeyen grupta %95,2 ve %88,3 olarak bulundu. S So on nu uç ç: : Bu çalışmada %4 oranında ikinci primer kanser gözlendi. Sigara ve alkol kullanan...

show abstract

“…Ott et al zeigten nochmals die Äquivalenz einer Dosis von 6 Gy mit einer Dosis von 3 Gy [19]. Danach wurde die in der Leitlinie [2] empfohlene Dosis nach dem ALARA-Prinzip (keep the dose as low as reasonably achievable) auf im Normalfall 3 Gy festgesetzt.…”

Section: Plantare Fasciitis/fersenspornunclassified

Analgetische Strahlentherapie gutartiger Erkrankungen des Skelettsystems

Niewald¹

2020

Arthritis und Rheuma

View full text Add to dashboard Cite

ZusammenfassungDer entzündungshemmende Effekt kleiner Strahlendosen ist seit Langem bekannt und strahlenbiologisch gut untermauert. Zahlreiche retrospektive Arbeiten und einige randomisierte Studien weisen darauf hin, dass ein gutes Ansprechen bei Enthesiopathien wie der Fasciitis plantaris, der Achillodynie, der Epicondylitis und z. B. der Tendinitis calcarea der Schulter zu erzielen ist (Ansprechraten von 60–80 %). Auch bei Arthrosen weisen retrospektive Daten auf eine gute Wirksamkeit der Strahlentherapie hin, der randomisierte Nachweis wird derzeit diskutiert und ist Studienfrage. Indiziert ist die Strahlentherapie bei Patienten im Alter von > 40 Jahren und einer minimalen Anamnesedauer von 3–6 Monaten. In dieser Zeit sollten die konservativen Therapiemethoden durchgeführt worden sein. Eine Gesamtdosis von 3–6 Gy wird in zweimal wöchentlichen Sitzungen über 3 Wochen appliziert. Während und nach der Strahlentherapie kann es zu einer kurzzeitigen Schmerzzunahme kommen. Das Ansprechen ist frühestens 3 Monate nach Therapie zu beurteilen. Nebenwirkungen wie z. B. Hautreaktionen werden überaus selten gesehen. Ein vielfach diskutiertes Tumorrisiko liegt nach bisherigen Daten im Sub-Promillebereich.

show abstract

Second primary malignancies in head and neck cancer patients

Abstract: The examinations revealed a high prevalence of curable stage SPM in HNSCC patients. Adapting a surveillance scheme including a chest CT is recommended.

Cited by 9 publications

References 29 publications

Malignite tanılı opere edilmiş ikinci primer akciğer kanserli hastaların uzun dönem sağkalımını etkileyen faktörlerin analizi

Malignite tanılı opere edilmiş ikinci primer akciğer kanserli hastaların uzun dönem sağkalımını etkileyen faktörlerin analizi

Second Primary Tumors in Patients with Head and Neck Cancer: A Retrospective Study from a Single Center

Analgetische Strahlentherapie gutartiger Erkrankungen des Skelettsystems

Contact Info

Product

Resources

About